Details of the Drug

General Information of Drug (ID: DMSHPW8)

Drug Name

Tolterodine

Synonyms

Tolterodina; Tolterodinum; Detrol (TN); Detrusitol (TN); Kabi-2234; 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol; 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol; 2-[3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol; 2-{(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl}-4-methylphenol

Indication

Disease Entry	ICD 11	Status	REF
Overactive bladder	GC50.0	Approved	[1]

Therapeutic Class

Antispasmodics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

325.5

Topological Polar Surface Area (xlogp)

5.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance: The drug present in the plasma can be removed from the body at the rate of 8.4 mL/min/kg [3]
Elimination: 1% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.9 - 3.7 hours [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 24.57769 micromolar/kg/day [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.037% [3]
Vd: The volume of distribution (Vd) of drug is 113 +/- 26.7 L [5]
Water Solubility: The ability of drug to dissolve in water is measured as 12 mg/mL [2]

Chemical Identifiers

Formula: C22H31NO
IUPAC Name: 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
Canonical SMILES: CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2
InChI: InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1
InChIKey: OOGJQPCLVADCPB-HXUWFJFHSA-N

Cross-matching ID

PubChem CID: 443879
ChEBI ID: CHEBI:9622
CAS Number: 124937-51-5
DrugBank ID: DB01036
TTD ID: D0BZ7W
INTEDE ID: DR1616
ACDINA ID: D00183

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M3 (CHRM3)	TTQ13Z5	ACM3_HUMAN	Antagonist	[6], [7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[9]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[8]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Overactive bladder

ICD Disease Classification

GC50.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Muscarinic acetylcholine receptor M3 (CHRM3)	DTT	CHRM3	4.61E-07	-0.59	-0.73
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	2.40E-01	-3.31E-02	-1.97E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tolterodine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Solifenacin.	Functional bladder disorder [GC50]	[53]
-----------

Coadministration of a Drug Treating the Disease Different from Tolterodine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Increased metabolism of Tolterodine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[54]
Oliceridine	DM6MDCF	Moderate	Additive CNS depression effects by the combination of Tolterodine and Oliceridine.	Acute pain [MG31]	[55]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[56]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[56]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Memantine.	Alzheimer disease [8A20]	[53]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Tolterodine caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[57]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Tolterodine caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[57]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Tolterodine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[57]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[53]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Tolterodine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[57]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Tolterodine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[57]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Tolterodine caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[57]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Cariprazine.	Bipolar disorder [6A60]	[53]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Tolterodine caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[57]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Tolterodine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[57]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Tolterodine when combined with Acetylcholine.	Cataract [9B10]	[58]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[59]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[59]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[59]
Dihydrocodeine	DMB0FWL	Moderate	Additive CNS depression effects by the combination of Tolterodine and Dihydrocodeine.	Chronic pain [MG30]	[60]
Arbutamine	DMCY8AF	Moderate	Increased risk of rapid heart rate by the combination of Tolterodine and Arbutamine.	Coronary atherosclerosis [BA80]	[61]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Tolterodine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[57]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Tolterodine caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[57]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Tolterodine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[57]
Sertraline	DM0FB1J	Minor	Decreased metabolism of Tolterodine caused by Sertraline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[62]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Tolterodine caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[57]
Escitalopram	DMFK9HG	Minor	Decreased metabolism of Tolterodine caused by Escitalopram mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[62]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Tolterodine and OPC-34712.	Depression [6A70-6A7Z]	[53]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Clomipramine.	Depression [6A70-6A7Z]	[53]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Doxepin.	Depression [6A70-6A7Z]	[53]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Mepenzolate.	Digestive system disease [DE2Z]	[53]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Oxybutynine.	Discovery agent [N.A.]	[53]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Tolterodine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[63]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Tolterodine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[57]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Tolterodine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[54]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[53]
Nadolol	DMW6GVL	Moderate	Additive CNS depression effects by the combination of Tolterodine and Nadolol.	Essential hypertension [BA00]	[54]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Tolterodine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[57]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Tolterodine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[57]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Tolterodine when combined with Pilocarpine.	Glaucoma [9C61]	[64]
Carvedilol	DMHTEAO	Moderate	Antagonize the effect of Tolterodine when combined with Carvedilol.	Heart failure [BD10-BD1Z]	[54]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Tolterodine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[57]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Tolterodine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[57]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Tolterodine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[65]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Tolterodine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Tolterodine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Tolterodine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Tolterodine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[66]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Tolterodine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Tolterodine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Acebutolol	DM0TI4U	Moderate	Antagonize the effect of Tolterodine when combined with Acebutolol.	Hypertension [BA00-BA04]	[54]
Penbutolol	DM4ES8F	Moderate	Additive CNS depression effects by the combination of Tolterodine and Penbutolol.	Hypertension [BA00-BA04]	[54]
Nebivolol	DM7F1PA	Moderate	Antagonize the effect of Tolterodine when combined with Nebivolol.	Hypertension [BA00-BA04]	[54]
Givosiran	DM5PFIJ	Minor	Decreased metabolism of Tolterodine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[62]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[53]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Tolterodine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[67]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Tolterodine and ITI-007.	Insomnia [7A00-7A0Z]	[53]
R0-93877	DMM4U9G	Moderate	Antagonize the effect of Tolterodine when combined with R0-93877.	Irritable bowel syndrome [DD91]	[68]
Glycerol phenylbutyrate	DMDGRQO	Minor	Decreased metabolism of Tolterodine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[62]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Tolterodine caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[57]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Tolterodine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[69]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Tolterodine caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[57]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Tolterodine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[70]
Dacomitinib	DMOH8VY	Minor	Decreased metabolism of Tolterodine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[62]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Tolterodine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[57]
Lumefantrine	DM29GAD	Minor	Decreased metabolism of Tolterodine caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[62]
Halofantrine	DMOMK1V	Minor	Decreased metabolism of Tolterodine caused by Halofantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[62]
Hydroxychloroquine	DMSIVND	Minor	Decreased metabolism of Tolterodine caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[62]
Primaquine	DMWQ16I	Minor	Decreased metabolism of Tolterodine caused by Primaquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[62]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Tolterodine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[57]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Tolterodine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[57]
Vemurafenib	DM62UG5	Minor	Decreased metabolism of Tolterodine caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[62]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Tolterodine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[54]
Danazol	DML8KTN	Moderate	Decreased metabolism of Tolterodine caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[57]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Tolterodine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[71]
Panobinostat	DM58WKG	Minor	Decreased metabolism of Tolterodine caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[62]
Neostigmine	DM6T2J3	Moderate	Antagonize the effect of Tolterodine when combined with Neostigmine.	Myasthenia gravis [8C6Y]	[72]
Ambenonium	DMOP0BL	Moderate	Antagonize the effect of Tolterodine when combined with Ambenonium.	Myasthenia gravis [8C6Y]	[72]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Tolterodine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[73]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Phenindamine.	Nasopharyngitis [CA00]	[53]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Promethazine.	Nausea/vomiting [MD90]	[53]
Rolapitant	DM8XP26	Minor	Decreased metabolism of Tolterodine caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[62]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Cyclizine.	Nausea/vomiting [MD90]	[53]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Tolterodine caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[57]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Tolterodine when combined with Metoclopramide.	Nausea/vomiting [MD90]	[74]
Bupropion	DM5PCS7	Minor	Decreased metabolism of Tolterodine caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[62]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Tolterodine caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[57]
Lorcaserin	DMG6OYJ	Minor	Decreased metabolism of Tolterodine caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[62]
Dexfenfluramine	DMJ7YDS	Minor	Decreased metabolism of Tolterodine caused by Dexfenfluramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[62]
Polythiazide	DMCH80F	Minor	Altered absorption of Tolterodine due to GI dynamics variation caused by Polythiazide.	Oedema [MG29]	[75]
Levomethadyl Acetate	DM06HG5	Moderate	Additive CNS depression effects by the combination of Tolterodine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[60]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Tolterodine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[57]
Oxymorphone	DM65AGJ	Moderate	Additive CNS depression effects by the combination of Tolterodine and Oxymorphone.	Pain [MG30-MG3Z]	[55]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Tolterodine and Dezocine.	Pain [MG30-MG3Z]	[55]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Flavoxate.	Pain [MG30-MG3Z]	[53]
Levodopa	DMN3E57	Moderate	Altered absorption of Tolterodine due to GI dynamics variation caused by Levodopa.	Parkinsonism [8A00]	[76]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Orphenadrine.	Parkinsonism [8A00]	[53]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Tolterodine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[77]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Methylscopolamine.	Peptic ulcer [DA61]	[53]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Tolterodine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[78]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Tolterodine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[57]
ABIRATERONE	DM8V75C	Minor	Decreased metabolism of Tolterodine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[62]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Tolterodine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[79]
Bicalutamide	DMZMSPF	Moderate	Decreased metabolism of Tolterodine caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[57]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[53]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Tolterodine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[80]
Oxamniquine	DM2QDX1	Minor	Decreased metabolism of Tolterodine caused by Oxamniquine mediated inhibition of CYP450 enzyme.	Schistosomiasis [1F86]	[62]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Quetiapine.	Schizophrenia [6A20]	[53]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Aripiprazole.	Schizophrenia [6A20]	[53]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Iloperidone.	Schizophrenia [6A20]	[53]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Paliperidone.	Schizophrenia [6A20]	[53]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Molindone.	Schizophrenia [6A20]	[53]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Thiothixene.	Schizophrenia [6A20]	[53]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Asenapine.	Schizophrenia [6A20]	[53]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Pimozide.	Schizophrenia [6A20]	[53]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Tolterodine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[57]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Tolterodine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[54]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Tolterodine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[57]
Armodafinil	DMGB035	Minor	Increased metabolism of Tolterodine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[81]
LEE011	DMMX75K	Moderate	Decreased metabolism of Tolterodine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[57]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Tolterodine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[54]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Tolterodine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[82]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[53]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[56]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Tolterodine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[53]
Propafenone	DMPIBJK	Minor	Decreased metabolism of Tolterodine caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[62]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Tolterodine caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[57]
-----------


⏷ Show the Full List of 127 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Ethyl acrylate	E00191	8821	Film/membrane-forming agent; Flavoring agent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Oleic acid	E00421	445639	Emulsifying agent; Penetration agent; Solubilizing agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Ammonia	E00007	222	Alkalizing agent
Brushite	E00392	104805	Diluent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Medium-chain triglyceride	E00640	Not Available	Emollient; Lubricant; Surfactant
Methyl methacrylate	E00133	6658	Film/membrane-forming agent
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 30 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Tolterodine 2 mg capsule	2 mg	24 HR Extended Release Oral Capsule	Oral
Tolterodine 4 mg capsule	4 mg	24 HR Extended Release Oral Capsule	Oral
Tolterodine 1 mg tablet	1 mg	Oral Tablet	Oral
Tolterodine 2 mg tablet	2 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6	Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53.
7	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
8	Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
9	Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics. Drug Metab Dispos. 2010 Sep;38(9):1456-63.
10	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
20	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
21	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
22	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
23	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
24	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
25	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
26	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
27	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
28	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
29	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
30	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
31	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
32	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
33	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
34	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
35	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
36	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
37	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
38	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
39	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
40	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
41	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
42	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
43	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
44	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
45	Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69.
46	M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5.
47	Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62.
48	Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
49	Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6.
50	Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94.
51	Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123.
52	Agonist-regulated alteration of the affinity of pancreatic muscarinic cholinergic receptors. J Biol Chem. 1993 Oct 25;268(30):22436-43.
53	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
54	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
55	Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
56	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
57	Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
58	Multum Information Services, Inc. Expert Review Panel.
59	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
60	Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
61	Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA.
62	Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
63	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
64	Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
65	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
66	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
67	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
68	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
69	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
70	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
71	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
72	Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
73	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
74	Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
75	Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
76	Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
77	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
78	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
79	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
80	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
81	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
82	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.